ClinicalTrials.gg
CompletedNCT05537584Updated Oct 30, 2026Results posted

SMART Trial to Predict Anhedonia Response to Antidepressant Treatment

A Phase 4 interventional study of Sertraline and Bupropion in Major Depressive Disorder, sponsored by Mclean Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Mclean Hospital · Phase 4, Interventional, and Treatment

How we know

Updated Oct 30, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies testing sertraline in Depressive Disorder, Major — 6 open to participants now, 7 under way, none of them phase 3. Sertraline · Depressive Disorder, Major.

Enrollment
26th of 44
57 · median 78
Started
2022
with 1 other
Phase 4
16 of 44
3 open now
Registered
36th of 44
by date
Lead sponsor
2 of 44
Mclean Hospital

Among the 44 studies testing sertraline in Depressive Disorder, Major, this one is the 26th largest by enrollment, is one of 2 that started in 2022, is one of 16 in phase 4, and was the 36th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

6 of the 44 studies testing sertraline in Depressive Disorder, Major are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About sertraline

Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing sertraline in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.

Read the detailed description

The treatment of depression is often trial-and-error. Earlier research reported that only 50% of individuals with depression show a significant decline in symptoms after taking an antidepressant. The situation is even worse in primary care, where only 30% respond to first line antidepressants.

The difficulty in treating depression is likely because treatment selection is not based on each person's characteristics. While some depressed individuals may benefit from selective serotonin reuptake inhibitors (SSRIs), others might benefit more from other types of medication. Finding markers that predict an individual's response to different antidepressants would provide patients and clinicians with valuable information to guide treatment selection.

The present study is among the first to use clinical (e.g., responses on questionnaires), behavioral (e.g., performance in computerized tasks), and brain (e.g., MRI scans) data to guide treatment selection in order to increase the likelihood of benefiting from one of two antidepressants. After analyzing an individuals' markers, subjects will be randomly assigned to receive a full 8-week course of an SSRI or non-SSRI.

Throughout the study, participants will complete 9 total sessions over the course of 9-10 weeks, including an electroencephalogram (EEG) recording, a functional magnetic resonance imaging (fMRI) scan, an electrocardiogram (EKG) exam, interviews with clinicians, and a full 8-week course of an antidepressant.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18 to 64
  • Any gender and all ethnic/racial origins
  • Diagnosis of Major Depressive Disorder. MDD diagnosis will be decided by clinicians via the Structured Clinical Interview for (SCID-5).
  • Elevated depression severity
  • Elevated anhedonia symptoms
  • Fluency in written and spoken English
  • Ability to give signed, either written or electronic
  • Normal or corrected-to-normal vision and hearing
  • Ability to adhere to the study schedule

Exclusion criteria

Exclusion Criteria:

  • Patient is currently enrolled in any treatment program except psychotherapy (transcranial magnetic stimulation, other antidepressants etc.).
  • Any to bupropion or sertraline considered unsafe by the study physician, or any history of adverse reaction to either drug.
  • Failure to respond to an adequate course of treatment with both of the study medications (sertraline or bupropion) during the current episode.
  • Participants who are determined to be treatment resistant, (i.e., having failed to respond to at least two adequate antidepressant trials in the current episode)
  • Pregnant women, or women of who have a positive result on a urine pregnancy test
  • Failure to meet MRI safety requirements, including any metal implants or prostheses that cannot be removed, or exposure to shrapnel
  • Claustrophobia or severe anxiety that might affect participation in neuroimaging
  • Injury or movement disorder that may make it difficult to lie still in the scanner
  • Any current recreational/illicit drug use, with the exception of THC, as assessed by a urine drug test (covering cocaine, cannabinoids, opiates, amphetamines, methamphetamines, phencyclidine, MDMA, benzodiazepines, methadone, oxycodone, tricyclic antidepressants, and barbiturates). Participants who use THC regularly will be allowed to continue in the study provided they have abstained for the three days prior to visits involving the MRI scan.
  • Use of Monoamine Oxidase Inhibitors (MAOIs) either currently or within the past two weeks
  • Participants who are currently stopping the use of tobacco products. Participants who cannot abstain from tobacco products for eight hours without cravings.
  • More than 15 alcohol-induced lifetime blackouts.
  • History of regular use (5-7xs per week) of marijuana before the age of 15
  • Lifetime history of other recreational drug use beyond the following limits (for each drug individually) and/or last use within the past 3 months:

    1. Hallucinogens (mushrooms, LSD): exclude for12 uses in the past year, or 15 uses lifetime (unless last use was 5+ years ago, then allow up to 25 lifetime uses)
    2. Ecstasy: exclude for 12 uses in the past year, or 15 uses lifetime (unless last use was 5+ years ago, then allow up to 25 lifetime uses)
    3. Anxiolytics (recreational use): exclude for 12 uses in the past year, or 15 uses life time (unless last use was 5+ years ago, then allow up to 25 lifetime uses)
    4. Cocaine, meth/psychostimulants (this includes prescribed stimulants such as methylphenidate) exclude for 5 uses in the past year, or 10 uses lifetime
    5. Prescribed opioids for a limited period (e.g., post-surgery) is OK if no use in the past 3 months
    6. 3 uses: Inhalants, IV drugs, crack cocaine, or crystal methamphetamine
  • Recent use (within 3 weeks) of any medication that affects blood flow or blood pressure, or which is vasodilating/vasoconstricting (for participants undergoing neuroimaging)
  • Metformin use in the past 6 months (for either clinical care or as part of research)
  • Serious or unstable medical illness
  • Current infectious illness (either transient or chronic); Current episode of allergic reaction or asthma
  • Hemophilia; Diabetes with poor glucose control; History of chronic migraine (> 15 days/mo.); History of dementia.
  • History of seizures or seizure disorder.
  • Any history of significant head injury or concussion with loss of consciousness for two minutes or more, or head injury with lingering functional/psychological impact
  • Serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems (contraindication to bupropion)- confirmed with at physicians' discretion.
  • Past/current diagnosis of: OCD, schizophrenia or other psychotic disorders, schizoaffective disorder, delusional disorder, psychotic disorders NOS, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, autism or any other pervasive developmental disorder, organic mental disorder, PTSD (current only), somatoform disorder, severe borderline or antisocial personality disorder, anorexia or current subthreshold anorexia, binge eating disorder, or bulimia (however bulimia is allowed if it has been fully remitted in the past 2 years; binge eating disorder is allowable if it has been partially remitted within the past 3 months; current subthreshold binge eating disorder is allowable; past PTSD fully remitted for longer than one month and current partial remission of PTSD is allowable)
  • Current mild, moderate, or severe substance (including cannabis) or alcohol use disorder. Early or sustained remission is allowable, i.e., criteria for any level of abuse has not been met for at least the past 3 months (with the exception of past or current cocaine, stimulant, or opioid abuse, which will lead to automatic exclusion).
  • Specific phobia, social anxiety disorder and generalized anxiety disorders will be allowed only if judged to be currently mild and never the principal diagnosis when co-occurring with current or past MDD. Panic disorder will be allowed if MDD is the principal diagnosis and panic disorder has been in remission for > 2 years.
  • Electroconvulsive Therapy in the current episode.
  • Patient is clinically unstable, in the judgment of the clinician or physician.
  • Participants with suicidal ideation where continued study participation is believed unsafe by the study clinician or study physician (these participants will be immediately referred to appropriate clinical treatment).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    MDD with SERT+ Response Marker

    Participants with MDD who have been classified as high sertraline responders based on behavioral and brain data.

    Drug: Sertraline · Drug: Bupropion

  • Experimental
    MDD with BUP+ Response Marker

    Participants with MDD who have been classified as high bupropion responders based on behavioral and brain data.

    Drug: Sertraline · Drug: Bupropion

Interventions

  • Subjects will receive 8 weeks of sertraline while monitored by the study physician

    Also known as: Zoloft

  • Subjects will receive 8 weeks of bupropion while monitored by the study physician

    Also known as: Wellbutrin

06

What researchers measure

Primary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS)

    The Montgomery-Åsberg Depression Rating Scale (MADRS) - Clinician-Rated Scale measures depressive symptom severity and is administered by a trained clinician. The scale includes 10 items assessing symptoms such as sadness, inner tension, sleep, appetite, concentration, energy, anhedonia, pessimistic thoughts, and suicidal thoughts. Each item is rated from 0-6, with a total score range of 0-60, calculated by summing all item scores. Higher scores indicate greater depression severity (worse outcome), whereas lower scores indicate fewer depressive symptoms (better outcome).

    Time frame: Baseline and Week 8 of treatment/outcome assessment session

Secondary outcomes

  1. Ventral-striatal Activation During Reward Related Tasks in an fMRI Scan

    Brain measure of anhedonia

    Time frame: 8-10 weeks

  2. Effort-based Decision Making During an Effort-based Task

    Behavioral measure of anhedonia

    Time frame: 8-10 weeks

  3. Reward Positivity During a Guessing Monetary Reward Task

    Behavioral measure of anhedonia

    Time frame: 8-10 weeks

  4. Cortico-insular Activation During an Effort-based Task

    Brain measure of anhedonia

    Time frame: 8-10 weeks

  5. Resting State Functional Connectivity Between the NAc and mPFC During an fMRI Scan

    Brain measure of anhedonia

    Time frame: 8-10 weeks

07

Results

Posted Oct 30, 2026
Limitations and caveats
Markers were derived from EMBARC, a multi-site trial, though the MRI sample was limited. The SMART-D trial included 48 participants, limiting power to detect effects, and larger samples may yield greater drug-specific differences. The use of resting-state fMRI may limit scalability, and harmonization across pipelines remains a challenge. Differences in response rates in SMART-D compared to EMBARC may reflect differences in sample characteristics or study design.

Participant flow

Participants were enrolled at McLean Hospital between September 30, 2022, and August 26, 2025. Eligible adults (18-64) met DSM-5-TR MDD criteria via SCID-5, with HRSD\>15 and SHAPS\>24, limited treatment resistance, and no major comorbidities or contraindications to the medications. All were medication-free, provided written informed consent, and were compensated.

Participant flow — Overall Study
MilestoneBupropion +/Sertraline + and BUP TreatmentBupropion +/Sertraline + and SER TreatmentBupropion +/Sertraline - and BUP TreatmentBupropion +/Sertraline - and SER TreamentBupropion -/Sertraline + and SER TreatmentBupropion -/Sertraline + and BUP TreatmentBupropion - /Sertraline - and BUP TreatmentBupropion -/Sertraline - and SER Treatment
Started777105525
Completed65583524
Not completed12222001
Withdrew: Lost to follow-up01001000
Withdrew: Withdrawal by subject10001000
Withdrew: Physician decision01220001

Outcome measures

PrimaryMontgomery-Åsberg Depression Rating Scale (MADRS)

The Montgomery-Åsberg Depression Rating Scale (MADRS) - Clinician-Rated Scale measures depressive symptom severity and is administered by a trained clinician. The scale includes 10 items assessing symptoms such as sadness, inner tension, sleep, appetite, concentration, energy, anhedonia, pessimistic thoughts, and suicidal thoughts. Each item is rated from 0-6, with a total score range of 0-60, calculated by summing all item scores. Higher scores indicate greater depression severity (worse outcome), whereas lower scores indicate fewer depressive symptoms (better outcome).

Time frame:
Baseline and Week 8 of treatment/outcome assessment session
Reported as:
Mean · Score on a scale
Montgomery-Åsberg Depression Rating Scale (MADRS)
Score on a scaleBupropion +/Sertraline + and BUP TreatmentBupropion +/Sertraline + and SER TreatmentBupropion +/Sertraline - and BUP TreatmentBupropion +/Sertraline - and SER TreatmentBupropion -/Sertraline + and SER TreatmentBupropion -/Sertraline + and BUP TreatmentBupropion - /Sertraline - and BUP TreatmentBupropion -/Sertraline - and SER Treatment
Montgomery-Åsberg Depression Rating Scale (MADRS)-20.33 ± 7.03-15.80 ± 15.55-11.60 ± 11.55-22.50 ± 8.14-22.00 ± 8.89-15.67 ± 6.66-12.00 ± 5.66-8.25 ± 11.03
Statistical analysis
  • Bupropion +/Sertraline + and BUP Treatment vs Bupropion +/Sertraline + and SER Treatment vs Bupropion +/Sertraline - and BUP Treatment vs Bupropion +/Sertraline - and SER Treatment vs Bupropion -/Sertraline + and SER Treatment vs Bupropion -/Sertraline + and BUP Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Mixed Models Analysis · p = <0.001 (LMM with participant-level random intercepts and random slopes for time; t(307) = -10.83.) · Time regression coefficient: -2.12 · 95% CI -2.51 to -1.74Negative values indicate decreasing MADRS scores. Estimate is the fixed-effect coefficient for time.
  • Bupropion +/Sertraline + and BUP Treatment vs Bupropion +/Sertraline + and SER Treatment vs Bupropion +/Sertraline - and BUP Treatment vs Bupropion +/Sertraline - and SER Treatment vs Bupropion -/Sertraline + and SER Treatment vs Bupropion -/Sertraline + and BUP Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Mixed Models Analysis · p = 0.37 (Time × received-drug interaction: F(1, 42.14) = 0.82.) · F statistic: -0.82F statistic for the time × treatment interaction; numerator df = 1 and denominator df = 42.14.
  • Bupropion +/Sertraline + and BUP Treatment vs Bupropion +/Sertraline + and SER Treatment vs Bupropion +/Sertraline - and BUP Treatment vs Bupropion +/Sertraline - and SER Treatment vs Bupropion -/Sertraline + and SER Treatment vs Bupropion -/Sertraline + and BUP Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Chi-squared · p = 0.81 · Chi-square statistic: 0.06SER: 68.0% (17/25); BUP: 61.9% (13/21). No significant difference was detected.
  • Bupropion +/Sertraline + and BUP Treatment vs Bupropion +/Sertraline + and SER Treatment vs Bupropion +/Sertraline - and BUP Treatment vs Bupropion +/Sertraline - and SER Treatment vs Bupropion -/Sertraline + and SER Treatment vs Bupropion -/Sertraline + and BUP Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Mixed Models Analysis · p = 0.87 (Time × consistency interaction: F(1, 38.18) = 0.03.) · F statistic: 0.03F statistic for the time × consistency interaction; numerator df = 1 and denominator df = 38.18.
  • Bupropion +/Sertraline + and BUP Treatment vs Bupropion +/Sertraline + and SER Treatment vs Bupropion +/Sertraline - and BUP Treatment vs Bupropion +/Sertraline - and SER Treatment vs Bupropion -/Sertraline + and SER Treatment vs Bupropion -/Sertraline + and BUP Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Chi-squared · p = 0.72 · Chi-square statistic: 0.13Inconsistent: 66.7% (14/21); consistent: 61.5% (16/26).
  • Bupropion +/Sertraline + and BUP Treatment vs Bupropion +/Sertraline + and SER Treatment vs Bupropion +/Sertraline - and BUP Treatment vs Bupropion +/Sertraline - and SER Treatment vs Bupropion -/Sertraline + and SER Treatment vs Bupropion -/Sertraline + and BUP Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Mixed Models Analysis · p = 0.029 (Time × marker-group interaction: F(2, 38.32) = 3.85.) · F statistic: 3.85Omnibus F statistic for differences in MADRS trajectories among the three marker groups; df = 2 and 38.32.
  • Bupropion +/Sertraline + and BUP Treatment vs Bupropion +/Sertraline + and SER Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Mixed Models Analysis · p = 0.080 (t(38.07) = -1.80.) · Difference in time slopes: -1.037 · 95% CI -2.17 to 0.100Neither-marker group was the reference. Negative values indicate a faster reduction in MADRS scores for the both-marker group.
  • Bupropion +/Sertraline - and BUP Treatment vs Bupropion +/Sertraline - and SER Treatment vs Bupropion -/Sertraline + and SER Treatment vs Bupropion -/Sertraline + and BUP Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Mixed Models Analysis · p = 0.019 (t(37.59) = -2.44.) · Difference in time slopes: -1.295 · 95% CI -2.335 to -0.256Neither-marker group was the reference. Negative values indicate a faster MADRS reduction in the one-marker group.
  • Bupropion +/Sertraline + and BUP Treatment vs Bupropion +/Sertraline + and SER Treatment vs Bupropion +/Sertraline - and BUP Treatment vs Bupropion +/Sertraline - and SER Treatment vs Bupropion -/Sertraline + and SER Treatment vs Bupropion -/Sertraline + and BUP Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Fisher Exact · p = 0.45 (Fisher's exact test; descriptive Pearson chi-square statistic = 1.71.) · Phi coefficient: 0.191Neither: 42.9% (3/7); one marker: 65.4% (17/26); both markers: 71.4% (10/14).
  • Bupropion +/Sertraline + and BUP Treatment vs Bupropion +/Sertraline + and SER Treatment vs Bupropion +/Sertraline - and BUP Treatment vs Bupropion +/Sertraline - and SER Treatment vs Bupropion -/Sertraline + and SER Treatment vs Bupropion -/Sertraline + and BUP Treatment vs Bupropion - /Sertraline - and BUP Treatment vs Bupropion -/Sertraline - and SER Treatment · Fisher Exact · p = 0.85 (Fisher's exact test; descriptive Pearson chi-square statistic = 0.39.) · Phi coefficient: 0.091Neither: 42.9% (3/7); one marker: 53.9% (14/26); both markers: 57.1% (8/14).
SecondaryVentral-striatal Activation During Reward Related Tasks in an fMRI Scan

Brain measure of anhedonia

Time frame:
8-10 weeks

Results for this outcome have not been posted.

SecondaryEffort-based Decision Making During an Effort-based Task

Behavioral measure of anhedonia

Time frame:
8-10 weeks

Results for this outcome have not been posted.

SecondaryReward Positivity During a Guessing Monetary Reward Task

Behavioral measure of anhedonia

Time frame:
8-10 weeks

Results for this outcome have not been posted.

SecondaryCortico-insular Activation During an Effort-based Task

Brain measure of anhedonia

Time frame:
8-10 weeks

Results for this outcome have not been posted.

SecondaryResting State Functional Connectivity Between the NAc and mPFC During an fMRI Scan

Brain measure of anhedonia

Time frame:
8-10 weeks

Results for this outcome have not been posted.

Adverse events

Collected over from enrollment until end of study procedures, up to 10 weeks of participation, including 8-week treatment period. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupropion +/Sertraline + and BUP Treatment0/7 (0%)0/7 (0%)1/7 (14.3%)
Bupropion +/Sertraline + and SER Treatment0/7 (0%)0/7 (0%)0/7 (0%)
Bupropion +/Sertraline - and BUP Treatment0/7 (0%)0/7 (0%)2/7 (28.6%)
Bupropion +/Sertraline - and SER Treatment0/10 (0%)0/10 (0%)2/10 (20%)
Bupropion -/Sertraline + and SER Treatment0/5 (0%)0/5 (0%)0/5 (0%)
Bupropion -/Sertraline + and BUP Treatment0/5 (0%)0/5 (0%)1/5 (20%)
Bupropion - /Sertraline - and BUP Treatment0/2 (0%)0/2 (0%)1/2 (50%)
Bupropion -/Sertraline - and SER Treatment0/5 (0%)0/5 (0%)1/5 (20%)
No Marker Assigned and no Medication0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventBupropion +/Sertraline + and BUP TreatmentBupropion +/Sertraline + and SER TreatmentBupropion +/Sertraline - and BUP TreatmentBupropion +/Sertraline - and SER TreatmentBupropion -/Sertraline + and SER TreatmentBupropion -/Sertraline + and BUP TreatmentBupropion - /Sertraline - and BUP TreatmentBupropion -/Sertraline - and SER TreatmentNo Marker Assigned and no Medication
Claustrophobic symptomsGeneral disorders0/70/71/70/100/50/50/20/51/1
Vasovagal response to blood drawGeneral disorders1/70/70/70/100/50/51/20/50/1
AppendicitisGastrointestinal disorders0/70/70/70/100/51/50/20/50/1
Side effect to medication: NauseaGeneral disorders0/70/70/72/100/50/50/20/50/1
Side-effects to medication: InsomniaGeneral disorders0/70/71/72/100/50/50/21/50/1
Side-effects to medication: Decreased appetiteGeneral disorders0/70/71/71/100/50/50/21/50/1
Side-effects to medication: HeadacheGeneral disorders0/70/70/71/100/50/50/21/50/1
Side-effects to medication: Worsen in depressive symptomsGeneral disorders0/70/71/70/100/50/50/20/50/1

Baseline characteristics

All randomized participants were included in the baseline characteristics analysis. All participants completed at least 1 week of treatment and had sufficient information to determine baseline biomarker status. Baseline characteristics are reported according to the randomized study arms, which correspond to biomarker status and randomized treatment assignment.

Age, Continuous
Age, Continuous(Years)Bupropion +/Sertraline + and BUP TreatmentBupropion +/Sertraline + and SER TreatmentBupropion +/Sertraline - and BUP TreatmentBupropion +/Sertraline - and SER TreatmentBupropion -/Sertraline + and SER TreatmentBupropion -/Sertraline + and BUP TreatmentBupropion - /Sertraline - and BUP TreatmentBupropion -/Sertraline - and SER TreatmentTotal
Mean28.14 ± 2.8535.29 ± 12.9425.86 ± 5.5530.60 ± 7.6627.00 ± 5.1033.40 ± 8.9120.50 ± 3.5423.40 ± 2.9729.0 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Bupropion +/Sertraline + and BUP TreatmentBupropion +/Sertraline + and SER TreatmentBupropion +/Sertraline - and BUP TreatmentBupropion +/Sertraline - and SER TreatmentBupropion -/Sertraline + and SER TreatmentBupropion -/Sertraline + and BUP TreatmentBupropion - /Sertraline - and BUP TreatmentBupropion -/Sertraline - and SER TreatmentTotal
Female5677322335
Male2103230213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bupropion +/Sertraline + and BUP TreatmentBupropion +/Sertraline + and SER TreatmentBupropion +/Sertraline - and BUP TreatmentBupropion +/Sertraline - and SER TreatmentBupropion -/Sertraline + and SER TreatmentBupropion -/Sertraline + and BUP TreatmentBupropion - /Sertraline - and BUP TreatmentBupropion -/Sertraline - and SER TreatmentTotal
American Indian or Alaska Native000000000
Asian1142101111
Native Hawaiian or Other Pacific Islander000000000
Black or African American010120004
White6334141325
More than one race000200002
Unknown or Not Reported020111016
08

Study locations

1 site
  • McLean Hospital
    Belmont, Massachusetts 02478, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We are part of a large team of researchers across the US called MCPsych which is funded through the Wellcome Leap Grant. We have a large repository of questionnaires, behavioral, and brain data that will be collected similar across sites and allow additional data analyses.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Within 12 months after data collection is completed

Access criteria: Access will be governed by the Multi-Channel Psych department of the Wellcome Leap foundation.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Aug 2025, 34 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 34 months is below that.

Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 13, 2022
StartActual
Sep 30, 2022
Primary completionActual
Aug 26, 2025
CompletionActual
Aug 26, 2025
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Enrollment
133→57
Oct 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedScore on Montgomery-AsbergÅsberg Depression Rating Scale (MADRS)Time frame: 8-10 weeks → Baseline and Week 8 of treatment/outcome assessment session
Oct 30, 2026
Documents
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedVentral-striatal activation during reward related tasksActivation During Reward Related Tasks in an fMRI scanScanTime frame: 8-10 weeks
  • EditedEffort-based decision making duringDecision Making During an effortEffort-based taskTaskTime frame: 8-10 weeks
  • EditedReward positivity duringPositivity During a guessing monetary reward taskGuessing Monetary Reward TaskTime frame: 8-10 weeks
  • EditedCortico-insular activation duringActivation During an effortEffort-based taskTaskTime frame: 8-10 weeks
  • EditedResting state functional connectivity betweenState Functional Connectivity Between the NAc and mPFC duringDuring an fMRI scanScanTime frame: 8-10 weeks
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Results posted
    Enrollment 133→57
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedScore on Montgomery-AsbergÅsberg Depression Rating Scale (MADRS)Time frame: 8-10 weeks → Baseline and Week 8 of treatment/outcome assessment session
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedVentral-striatal activation during reward related tasksActivation During Reward Related Tasks in an fMRI scanScanTime frame: 8-10 weeks
    • EditedEffort-based decision making duringDecision Making During an effortEffort-based taskTaskTime frame: 8-10 weeks
    • EditedReward positivity duringPositivity During a guessing monetary reward taskGuessing Monetary Reward TaskTime frame: 8-10 weeks
    • EditedCortico-insular activation duringActivation During an effortEffort-based taskTaskTime frame: 8-10 weeks
    • EditedResting state functional connectivity betweenState Functional Connectivity Between the NAc and mPFC duringDuring an fMRI scanScanTime frame: 8-10 weeks
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05537584
Lead sponsor
Mclean Hospital
Responsible party
Diego Pizzagalli (Professor, Department of Psychiatry, Harvard Medical School, Mclean Hospital) — Principal investigator
First posted
Sep 13, 2022
Start date
Sep 30, 2022
Primary completion
Aug 26, 2025
Completion
Aug 26, 2025
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Diego A. Pizzagalli, PhD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sertraline · Bupropion

Start the discussion